Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas
Blood Research
; : 187-192, 2016.
Article
en En
| WPRIM
| ID: wpr-209254
Biblioteca responsable:
WPRO
ABSTRACT
BACKGROUND: This study aimed to assess the treatment outcomes of ifosphamide, mesna, etoposide, and prednisolone (IMEP) combination regimen as a front-line chemotherapy in patients with peripheral T-cell lymphomas (PTCLs). METHODS: Clinical data of 38 newly diagnosed PTCLs patients who underwent IMEP at Busan Paik Hospital from January 2002 to December 2013 were retrospectively analyzed. RESULTS: The overall response rate was 68.5%, with 21 (55.3%) complete response/complete response unconfirmed and 6 (15.8%) partial response (PR). The median follow-up duration was 25.5 months (range, 0.2-87.3). The median overall survival was not reached and 2-year survival rate was 67%. The median progression free survival was 23 months. The most frequently reported adverse effects higher than grade 3 were hematologic toxicities including neutropenia (68.4%), thrombocytopenia (42.1%). There was no treatment-related mortality. CONCLUSION: IMEP regimen is effective and safe as a front-line chemotherapy in patients with PTCLs.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Trombocitopenia
/
Prednisolona
/
Tasa de Supervivencia
/
Estudios Retrospectivos
/
Estudios de Seguimiento
/
Mortalidad
/
Linfoma de Células T Periférico
/
Mesna
/
Supervivencia sin Enfermedad
/
Quimioterapia
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Blood Research
Año:
2016
Tipo del documento:
Article